83 5.2.2.1, p.85 ,
Discussion, Partie, vol.4, p.91 ,
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms, Leukemia, vol.5, issue.1, 2008. ,
DOI : 10.1038/sj.leu.2404955
JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients, Leukemia, vol.365, issue.3, 2006. ,
DOI : 10.1111/j.1365-2141.2005.05764.x
The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms, Human Pathology, vol.39, issue.6, pp.534-539, 2008. ,
DOI : 10.1016/j.humpath.2008.02.004
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression, Blood, vol.108, issue.12, pp.3913-3918, 2006. ,
DOI : 10.1182/blood-2006-03-008805
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders, Blood, vol.106, issue.6, pp.2162-2170, 2005. ,
DOI : 10.1182/blood-2005-03-1320
Epidemiology of the Myeloproliferative Disorders Polycythemia Vera and Essential Thrombocythemia, Seminars in Thrombosis and Hemostasis, vol.32, issue.3, pp.171-174, 2006. ,
DOI : 10.1055/s-2006-939430
Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study, Haematologica, vol.94, issue.6, pp.865-874, 2009. ,
DOI : 10.3324/haematol.2008.004234
Prevalence of polycythemia vera and essential thrombocythemia, American Journal of Hematology, vol.139, issue.5, pp.359-62, 2008. ,
DOI : 10.1002/ajh.21129
The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis, 11. SFH. Polyglobulie primitive ou maladie de Vaquez. Hématologie, pp.470-5331, 2003. ,
DOI : 10.7326/0003-4819-139-6-200309160-00009
Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99, Journal of Internal Medicine, vol.22, issue.1, pp.161-166, 2004. ,
DOI : 10.1034/j.1600-0609.2000.90236.x
Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol Epidemiological data in polycythaemia vera: a study of 842 cases, Hematol Cell Ther, vol.1540, issue.44, pp.173-89159, 1997. ,
Diagnosis and classification of the polycythemias, Semin Hematol, 1975. ,
World Health Organization of Tumors of Hematopoietic and Lymphoid tissues, 1920. ,
Thrombocytémie, carence martiale sans anémie : le concept d'une polyglobulie primitive masquée. La revue de gériatrie, pp.355-60, 1999. ,
Stratégie diagnostique devant un prurit. Médecine thérapeutique, 2000. ,
Acute leucocytoclastic vasculitis and aquagenic pruritus long preceding polycythemia rubra vera, Eur J Dermatol, vol.12, issue.3, pp.270-271, 2002. ,
Inapparent Polycythemia Vera: An Unrecognized Diagnosis, The American Journal of Medicine, vol.102, issue.1, pp.14-20, 1997. ,
DOI : 10.1016/S0002-9343(96)00351-8
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders, Journal of Thrombosis and Haemostasis, vol.18, issue.2, pp.708-722, 2007. ,
DOI : 10.1182/blood-2003-02-0443
Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis, Blood, vol.108, issue.9, pp.3223-3227, 2006. ,
DOI : 10.1182/blood-2006-05-021527
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders, Am J Med Leukemia, vol.11722, issue.275, pp.755-61905, 2004. ,
/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Br J Haematol. Blood. Jul, vol.600100114, issue.305, pp.15-23937, 1998. ,
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs), Cancer, vol.33, issue.1, pp.68-76, 2007. ,
DOI : 10.1002/cncr.22365
Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area, European Journal of Haematology, vol.65, issue.2, 2000. ,
DOI : 10.1034/j.1600-0609.2000.90236.x
Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?, Haematologica, vol.93, issue.2, 2008. ,
DOI : 10.3324/haematol.12002
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT), Leukemia Research, vol.31, issue.6, 2007. ,
DOI : 10.1016/j.leukres.2006.12.002
Twentyfive years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France) Haematologica Woodliff HJ, Dougan L. Myelofibrosis in Western Australia: an epidemiological study of 29 cases Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, Med J Aust Apr, vol.961112, issue.361, pp.55-61523, 1976. ,
Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995, Am J Hematol. Ridell B, Carneskog J Eur J Haematol, vol.61, issue.38, pp.10-15, 1983. ,
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis, Blood, vol.110, issue.3, pp.267-71986, 2007. ,
DOI : 10.1182/blood-2006-12-064626
Pathogenesis of Myelofibrosis With Myeloid Metaplasia, Journal of Clinical Oncology, vol.23, issue.33, pp.8520-8550, 2005. ,
DOI : 10.1200/JCO.2004.00.9316
Agnogenic Myeloid Metaplasia, Radiology, vol.72, issue.5, pp.189-94, 1978. ,
DOI : 10.1148/72.5.716
La splénomégalie myéloïde : De données récentes à un modèle physiopathologique. Hématologie Value of bone marrow biopsy in the diagnosis of essential thrombocythemia, Haematologica, vol.889, issue.438, pp.187-96911, 2002. ,
Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes, Blood, vol.47111, issue.451, pp.1774-8160, 2006. ,
Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis, Histopathology, vol.88, issue.6, pp.758-67, 2010. ,
DOI : 10.1111/j.1365-2559.2010.03545.x
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification, Blood, vol.117, issue.21, pp.5710-5718, 2011. ,
DOI : 10.1182/blood-2010-07-293761
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study, Journal of Clinical Oncology, vol.29, issue.23, pp.3179-84, 2011. ,
DOI : 10.1200/JCO.2010.34.5298
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation, Leukemia, vol.38, issue.11, pp.2020-2028, 2008. ,
DOI : 10.1038/leu.2008.253
Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera, Journal of Clinical Oncology, vol.23, issue.10, pp.2224-2256, 2005. ,
DOI : 10.1200/JCO.2005.07.062
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia., Journal of Clinical Oncology, vol.8, issue.3, pp.556-62, 1990. ,
DOI : 10.1200/JCO.1990.8.3.556
Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked, Haematologica, vol.95, issue.10, 2010. ,
DOI : 10.3324/haematol.2010.025064
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases, Blood, vol.111, issue.10, pp.1788-91, 2008. ,
DOI : 10.1182/blood-2007-11-125328
Role of theJAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis, Hepatology, vol.51, issue.6, pp.1528-1562, 2006. ,
DOI : 10.1002/hep.21435
tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis, International Journal of Laboratory Hematology, vol.280, issue.5, pp.415-424, 2008. ,
DOI : 10.1111/j.1751-553X.2007.00973.x
Platelets and Thrombosis in Myeloproliferative Diseases, Hematology, vol.2005, issue.1, pp.409-424, 2005. ,
DOI : 10.1182/asheducation-2005.1.409
Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia, Lancet, vol.2, issue.8102, pp.1219-1241, 1978. ,
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood Leukocytosis and risk stratification assessment in essential thrombocythemia Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, J Clin Oncol Jun, vol.10926110, issue.623, pp.2446-522732, 2007. ,
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost, Br J Haematol. Feb, vol.12832, issue.646, pp.275-90589, 2005. ,
Diagnosis and treatment of polycythemia vera and essential thrombocythemia, Hematol J, vol.5, issue.1, pp.255-63, 2011. ,
Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post???Polycythemia Vera/Essential Thrombocythemia Myelofibrosis, Journal of Clinical Oncology, vol.27, issue.33, pp.5587-93, 2009. ,
DOI : 10.1200/JCO.2009.22.8833
Assessing New Therapies and Their Overall Impact in Myelofibrosis, Hematology, vol.2010, issue.1, pp.115-136 ,
DOI : 10.1182/asheducation-2010.1.115
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients, Haematologica, vol.93, issue.11, pp.1645-51, 2008. ,
DOI : 10.3324/haematol.13346
Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors, Mayo Clinic Proceedings, vol.81, issue.2, pp.159-66, 2006. ,
DOI : 10.4065/81.2.159
Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients, British Journal of Haematology, vol.83, issue.3, pp.786-90, 2002. ,
DOI : 10.1046/j.1365-2141.2002.03688.x
Hématologie clinique et biologique, 2005. ,
Philadelphianegative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet, J Clin Oncol Feb, vol.2029, issue.6, pp.761-70, 2011. ,
Blast phase of essential thrombocythemia: A single center study, American Journal of Hematology, vol.107, issue.10, pp.641-645, 2009. ,
DOI : 10.1002/ajh.21496
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence, Br J Haematol, 2010. ,
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study, Blood, vol.105, issue.7, pp.2664-70, 2005. ,
DOI : 10.1182/blood-2004-09-3426
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia, Leuk Lymphoma, vol.37, pp.3-4379, 2000. ,
Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan, P. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes, pp.3749-79616, 1998. ,
How I treat patients with polycythemia vera, Blood, vol.109, issue.12, pp.5104-5115, 2007. ,
DOI : 10.1182/blood-2006-12-038968
Conventional cytogenetics in myelofibrosis: literature review and discussion, European Journal of Haematology, vol.110, issue.5, pp.329-367, 2009. ,
DOI : 10.1111/j.1600-0609.2009.01224.x
Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates Myeloproliferative disorders, Eur J Haematol. Bench AJ Best Pract Res Clin Haematol, vol.8014, issue.863, pp.197-200531, 2001. ,
Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance, European Journal of Haematology, vol.255, issue.1, pp.17-21, 2009. ,
DOI : 10.1111/j.1600-0609.2009.01246.x
Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia, 2008. ,
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics, Nature Reviews Clinical Oncology, vol.133, issue.11, pp.1818-27627, 2009. ,
DOI : 10.1038/nrclinonc.2009.149
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies, Oncotarget, vol.2, issue.6, pp.485-90, 2011. ,
DOI : 10.18632/oncotarget.281
ASXL1 mutations in primary and secondary myelofibrosisAvailable on line. 92 A gain-of-function mutation of JAK2 in myeloproliferative disorders, Br J Haematol N Engl J Med, vol.352, issue.17, pp.1779-90, 2005. ,
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, pp.387-97, 2005. ,
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.100, issue.7037, pp.1144-1152, 2005. ,
DOI : 10.1182/blood-2002-09-2839
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, pp.1054-61, 2005. ,
JAK2, the??JAK2 V617F mutant and??cytokine receptors, Pathologie Biologie, vol.55, issue.2, pp.88-91, 2007. ,
DOI : 10.1016/j.patbio.2006.06.003
Jak2: normal function and role in hematopoietic disorders, Current Opinion in Genetics & Development, vol.17, issue.1, pp.8-14, 2007. ,
DOI : 10.1016/j.gde.2006.12.009
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia, Blood, vol.108, issue.7, pp.2435-2442, 2006. ,
DOI : 10.1182/blood-2006-04-018259
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera, Blood, vol.110, issue.3, pp.1013-1034, 2007. ,
DOI : 10.1182/blood-2006-10-054940
The Myeloproliferative Disorders, New England Journal of Medicine, vol.355, issue.23, pp.2452-66, 2006. ,
DOI : 10.1056/NEJMra063728
Biologie moléculaire de la cellule, 2005. ,
Concomitant neutrophil JAK2V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia, British Journal of Haematology, vol.95, issue.2, pp.166-71, 2005. ,
DOI : 10.1074/jbc.C500138200
JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?, Leukemia, vol.20, issue.11, p.2067, 2006. ,
DOI : 10.1182/blood-2005-03-1320
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms, pp.1128-1166, 2010. ,
JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5, Leukemia, vol.24, issue.5, 2010. ,
DOI : 10.3324/haematol.13081
Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera, Leukemia, vol.19, issue.12, pp.2210-2211, 2006. ,
DOI : 10.1038/sj.leu.2404419
The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors, Leukemia, vol.256, issue.9, p.1622, 2006. ,
DOI : 10.1038/sj.leu.2404292
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population, Haematologica, vol.96, issue.3, pp.450-453, 2011. ,
DOI : 10.3324/haematol.2010.033191
JAK2V617F: prevalence in a large Chinese hospital population, Blood, vol.109, issue.1, pp.339-381, 2007. ,
DOI : 10.1182/blood-2006-03-009472
mutation detectable in healthy volunteers?, American Journal of Hematology, vol.94, issue.4, pp.287-295, 2010. ,
DOI : 10.1002/ajh.21627
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia, Blood, vol.106, issue.10, pp.3377-3386, 2005. ,
DOI : 10.1182/blood-2005-05-1898
Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7, Blood, vol.107, issue.3, pp.1242-1245, 2006. ,
DOI : 10.1182/blood-2005-09-3644
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes, Blood, vol.106, issue.4, pp.1207-1216, 2005. ,
DOI : 10.1182/blood-2005-03-1183
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation, Blood, vol.108, issue.7, pp.2173-81, 2006. ,
DOI : 10.1182/blood-2006-02-005751
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors, Blood, vol.113, issue.23, pp.5727-5763, 2009. ,
DOI : 10.1182/blood-2009-02-205237
The Role of JAK2 Mutations in RARS and Other MDS, Hematology, vol.2008, issue.1, pp.52-61, 2008. ,
DOI : 10.1182/asheducation-2008.1.52
Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis, Haematologica, vol.91, issue.5, pp.719-739, 2006. ,
The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia, pp.2060-2061, 2006. ,
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis, Haematologica, vol.93, issue.1, pp.34-40, 2008. ,
DOI : 10.3324/haematol.11581
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis, N Engl J Med Feb, vol.1356, issue.5, pp.459-68, 2007. ,
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications, Leukemia, vol.22, issue.9, 2010. ,
DOI : 10.1038/leu.2010.148
Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis, Blood, vol.111, issue.11, pp.5400-5402, 2008. ,
DOI : 10.1182/blood-2008-02-137703
The JAK2 exon 12 mutations: A comprehensive review, American Journal of Hematology, vol.106, issue.8, 2011. ,
DOI : 10.1002/ajh.22063
Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs, Leukemia Research, vol.32, issue.9, pp.1485-1492, 2008. ,
DOI : 10.1016/j.leukres.2008.01.002
Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients, Leukemia, vol.365, issue.4, pp.870-873, 2008. ,
DOI : 10.1111/j.1365-2141.2007.06497.x
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia, 2007. ,
Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations, Blood, vol.111, issue.7, pp.3863-3869, 2008. ,
DOI : 10.1182/blood-2007-09-111971
Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations, Am J Clin Pathol, 2010. ,
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood, pp.2813-2819, 2011. ,
Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients, PLoS ONE, vol.5, issue.1, p.8893, 2010. ,
DOI : 10.1371/journal.pone.0008893.t001
Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis, Proceedings of the National Academy of Sciences, vol.101, issue.31, pp.11444-11451, 2004. ,
DOI : 10.1073/pnas.0404241101
MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia, PLoS Medicine, vol.102, issue.7, p.270, 2006. ,
DOI : 10.1371/journal.pmed.0030270.st001
exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis, British Journal of Haematology, vol.35, issue.2, pp.250-257, 2010. ,
DOI : 10.1111/j.1365-2141.2010.08083.x
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor, Blood, vol.107, issue.5, pp.1864-71, 2006. ,
DOI : 10.1182/blood-2005-06-2600
Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients, Leukemia, vol.25, issue.12, 2011. ,
DOI : 10.1182/blood-2009-04-216044
W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes, Hematological Oncology, vol.110, issue.5, pp.33-42, 2010. ,
DOI : 10.1002/hon.899
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, vol.108, issue.10, pp.3472-3478, 2006. ,
DOI : 10.1182/blood-2006-04-018879
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort, Blood, vol.112, issue.1, pp.141-150, 2008. ,
DOI : 10.1182/blood-2008-01-131664
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms, Blood, vol.116, issue.6, pp.988-92, 2010. ,
DOI : 10.1182/blood-2010-02-270108
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F, Journal of Leukocyte Biology, vol.85, issue.6, pp.957-65, 2009. ,
DOI : 10.1189/jlb.0908575
Mutation???Negative Erythrocytosis, New England Journal of Medicine, vol.363, issue.12, pp.1189-90, 2010. ,
DOI : 10.1056/NEJMc1006966
Possible new LNK mutations in myeloproliferative neoplasms, American Journal of Hematology, vol.86, issue.10, pp.866-874, 2011. ,
DOI : 10.1002/ajh.22107
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations, Leukemia, vol.118, issue.10, pp.1713-1721, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-3783
Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell, pp.423-457, 2011. ,
Emerging roles of TET proteins and 5- hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle, Aug, vol.1510, issue.16, pp.2662-2670, 2011. ,
Genetics of the myeloproliferative neoplasms, Curr Opin Hematol, 2011. ,
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, Leukemia, vol.22, issue.5, pp.905-916, 2009. ,
DOI : 10.1038/leu.2009.47
in Myeloid Cancers, New England Journal of Medicine, vol.360, issue.22, pp.2289-301, 2009. ,
DOI : 10.1056/NEJMoa0810069
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms, pp.1343-1348, 2009. ,
TET2 mutations in childhood leukemia, Leukemia, vol.25, issue.1, pp.189-92, 2011. ,
DOI : 10.1038/nature09303
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates, Leukemia, vol.16, issue.5, 2009. ,
DOI : 10.1038/leu.2009.37
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res, pp.447-52, 2010. ,
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders, Nature Genetics, vol.8, issue.8, pp.722-728, 2010. ,
DOI : 10.1016/j.molcel.2008.10.016
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms, Leukemia, vol.25, issue.7, pp.1200-1202, 2010. ,
DOI : 10.1182/blood-2010-06-293415
New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 2011. ,
How I treat essential thrombocythemia. Blood, Feb, vol.3117, issue.5, pp.1472-82, 2011. ,
Diagnosis and treatment of polycythemia vera and essential thrombocythemia. Hematology Education: Annual congress of the European Hematology Association, pp.255-63, 2011. ,
Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series: Polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management, American Journal of Hematology, vol.110, issue.3, pp.292-301, 2011. ,
DOI : 10.1002/ajh.21946
Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera, New England Journal of Medicine, vol.350, issue.2, pp.114-138, 2004. ,
DOI : 10.1056/NEJMoa035572
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood, pp.1205-1215, 2010. ,
The haematocrit and platelet target in polycythemia vera, British Journal of Haematology, vol.128, issue.2, pp.249-59, 2007. ,
DOI : 10.1007/BF01707281
Polycythemia vera: myths, mechanisms, and management, Blood, vol.100, issue.13, pp.4272-90, 2002. ,
DOI : 10.1182/blood-2001-12-0349
Management of polycythemia vera with hydroxyurea, Semin Hematol, vol.34, issue.1, pp.24-32, 1997. ,
Hydroxyurea in the Treatment of Polycythemia Vera: A Prospective Study of 100 Patients Over a 20-Year Period, Southern Medical Journal, vol.80, issue.3, pp.323-330, 1987. ,
DOI : 10.1097/00007611-198703000-00012
Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980, Journal of Clinical Oncology, vol.29, issue.29, pp.3907-3920, 2011. ,
DOI : 10.1200/JCO.2011.36.0792
An inconvenient truth. Blood, pp.2727-2735, 2010. ,
Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia, Curr Hematol Rep, vol.2, issue.3, pp.257-63, 2003. ,
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera, Journal of Clinical Oncology, vol.27, issue.32, pp.5418-5442, 2009. ,
DOI : 10.1200/JCO.2009.23.6075
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera, Blood, vol.112, issue.8, pp.3065-72, 2008. ,
DOI : 10.1182/blood-2008-03-143537
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process, British Journal of Haematology, vol.22, issue.6, pp.961-964, 2010. ,
DOI : 10.1111/j.1365-2141.2009.08019.x
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference, Blood, vol.113, issue.20, pp.4829-4862, 2009. ,
DOI : 10.1182/blood-2008-09-176818
The effects of anagrelide on human megakaryocytopoiesis, British Journal of Haematology, vol.99, issue.1, pp.174-80, 1997. ,
DOI : 10.1046/j.1365-2141.1997.3503164.x
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia, New England Journal of Medicine, vol.353, issue.1, pp.33-45, 2005. ,
DOI : 10.1056/NEJMoa043800
Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leuk Lymphoma, pp.47-56, 1996. ,
Pruritus in polycythaemia vera: prevalence, laboratory correlates and management, British Journal of Haematology, vol.96, issue.3, pp.619-640, 2001. ,
DOI : 10.1016/S0140-6736(88)92254-4
Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood, p.2627, 2002. ,
Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera, British Journal of Dermatology, vol.71, issue.5, pp.979-81, 2002. ,
DOI : 10.1046/j.1365-2133.1998.02403.x
Interferon alpha in the treatment of polycythemia vera ,
Targeting myeloproliferative neoplasms with JAK inhibitors, Current Opinion in Hematology, vol.18, issue.2, pp.105-115, 2011. ,
DOI : 10.1097/MOH.0b013e3283439964
Les syndromes myéloprolifératifs, 2008. ,
Rethinking Disease Definitions and Therapeutic Strategies in Essential Thrombocythemia and Polycythemia Vera, Hematology, vol.2010, issue.1, pp.129-163 ,
DOI : 10.1182/asheducation-2010.1.129
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients, Leukemia, vol.25, issue.1, pp.82-90, 2011. ,
DOI : 10.1111/j.1365-2141.2007.06776.x
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status, Journal of Clinical Oncology, vol.29, issue.4, pp.392-399, 2011. ,
DOI : 10.1200/JCO.2010.32.2446
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment, Blood, vol.113, issue.13, pp.2895-901, 2009. ,
DOI : 10.1182/blood-2008-07-170449
Predictors of greater than 80% two-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically-annotated patients. Blood, 2011. ,
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study, Journal of Clinical Oncology, vol.29, issue.10, pp.1356-63, 2011. ,
DOI : 10.1200/JCO.2010.32.9490
Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions, Leukemia, vol.30, issue.8, pp.1827-1835, 2007. ,
DOI : 10.1038/sj.leu.2404711
Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): Clinicopathologic comparison of del(5q)-positive and -negative cases, Leukemia Research, vol.32, issue.12, 2008. ,
DOI : 10.1016/j.leukres.2008.04.022
How I treat myelofibrosis. Blood, pp.3494-504, 2011. ,
Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature, British Journal of Haematology, vol.86, issue.4, pp.399-403, 2004. ,
DOI : 10.1016/S0268-960X(97)90022-9
Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level, European Journal of Haematology, vol.82, issue.2 ,
DOI : 10.1111/j.1600-0609.2009.01266.x
Low-dose thalidomide in myelofibrosis, Haematologica, vol.93, issue.7, pp.1100-1101, 2008. ,
DOI : 10.3324/haematol.12416
Thalidomide en 2005 : mise au point et utilisation pratique Journal de pharmacie clinique. 2005 juillet-août-septembre, pp.145-57 ,
Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha, British Journal of Haematology, vol.95, issue.1, pp.101-104, 2003. ,
DOI : 10.1182/blood-2002-01-0335
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood Site internet, pp.4436-4444, 0197. ,
How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood, 2009. ,
The role of splenectomy in myelofibrosis with myeloid metaplasia. Minerva Chir, pp.619-644, 2010. ,
Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic, Cancer, vol.91, issue.2, pp.361-70, 2006. ,
DOI : 10.1002/cncr.22021
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci??t?? Fran??aise de Greffe de Moelle et de Th??rapie Cellulaire (SFGM-TC), British Journal of Haematology, vol.27, issue.3, pp.331-340, 2011. ,
DOI : 10.1111/j.1365-2141.2010.08417.x
Outcome of Transplantation for Myelofibrosis, Biology of Blood and Marrow Transplantation, vol.16, issue.3, pp.358-67, 2010. ,
DOI : 10.1016/j.bbmt.2009.10.025
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type, Bone Marrow Transplantation, vol.28, issue.3, pp.458-63, 2010. ,
DOI : 10.1097/01.moh.0000203191.99447.98
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Haematologica, vol.93, issue.10, pp.1514-1536, 2008. ,
DOI : 10.3324/haematol.12828
Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood, Feb, vol.1109, issue.3, pp.1316-1337, 2007. ,
A phase-2 trial of low-dose pomalidomide in myelofibrosis, Leukemia, vol.85, issue.2, pp.301-305, 2011. ,
DOI : 10.1182/blood-2009-08-240135
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis, New England Journal of Medicine, vol.363, issue.12, pp.1117-1144, 2010. ,
DOI : 10.1056/NEJMoa1002028
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations, Leukemia, vol.112, issue.2, pp.218-243, 2011. ,
DOI : 10.1016/j.ccr.2009.10.015
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms, Leukemia, vol.63, issue.4, 2011. ,
DOI : 10.1172/JCI42442
Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis, Leukemia, vol.20, issue.8, pp.1824-1830, 2007. ,
DOI : 10.1038/sj.leu.2404730
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation, Blood, vol.109, issue.9, pp.4106-4113, 2007. ,
DOI : 10.1182/blood-2006-12-061135
Insights into JAK2-V617F mutation in CML, The Lancet Oncology, vol.8, issue.10, pp.863-867, 2007. ,
DOI : 10.1016/S1470-2045(07)70294-2
Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia, Leukemia, vol.13, issue.1, p.216, 2008. ,
DOI : 10.1038/sj.leu.2404953
Terminal differentiation of hemopoietic cell clones cultured in tridimensional collagen matrix: in situ cell morphology and enzyme histochemistry analysis, Biology of the Cell, vol.50, issue.2, pp.107-127, 1984. ,
DOI : 10.1111/j.1768-322X.1984.tb00257.x
Serum‐free medium allows the optimal growth of human megakaryocyte progenitors compared with human plasma supplemented cultures: Role of TGF β, Stem Cells, vol.77, issue.2, pp.120-129, 1993. ,
DOI : 10.1002/stem.5530110207
Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera, The Hematology Journal, vol.5, issue.2, pp.161-168, 2004. ,
DOI : 10.1038/sj.thj.6200344
A standardized endogenous megakaryocytic erythroid colony assay for the diagnosis of essential thrombocythemia, Haematologica, vol.89, issue.10, pp.1207-1219, 2004. ,
Stem Cell Assays, 2008. ,
DOI : 10.1007/978-1-59745-536-7
Human hematopoietic colonies in health and disease, Acta Haematol, vol.113, issue.1, pp.5-96, 2005. ,
DOI : 10.1159/isbn.978-3-318-01187-6
Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders, The Journal of Molecular Diagnostics, vol.9, issue.2, pp.272-278, 2007. ,
DOI : 10.2353/jmoldx.2007.060133
A clinical update in polycythemia vera and essential thrombocythemia, The American Journal of Medicine, vol.109, issue.2, pp.141-150, 2000. ,
DOI : 10.1016/S0002-9343(00)00449-6
The significance of endogenous erythroid colonies (EEC) in haematological disorders, Blood Reviews, vol.1, issue.2, pp.133-173, 1987. ,
DOI : 10.1016/0268-960X(87)90008-7
JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones, Leuk Res, 2010. ,
Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques, Blood Transfus, vol.7, issue.3, pp.204-213, 2009. ,
Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders, Blood, vol.102, issue.5, pp.1869-71, 2003. ,
DOI : 10.1182/blood-2003-03-0744
JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV), Leukemia Research, vol.33, issue.1, pp.54-63, 2009. ,
DOI : 10.1016/j.leukres.2008.07.008
The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients, Blood, vol.106, issue.8, pp.2862-2866, 2005. ,
DOI : 10.1182/blood-2005-04-1515
JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders, Leukemia, vol.9, issue.4, pp.736-743, 2006. ,
DOI : 10.1038/sj.leu.2404123
JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility, The Journal of Molecular Diagnostics, vol.8, issue.4, pp.397-411, 2006. ,
DOI : 10.2353/jmoldx.2006.060007
Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?, Leukemia, vol.22, issue.2, 2008. ,
DOI : 10.1055/s-2006-939433
Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase, Haematologica, vol.95, issue.11, pp.1960-1963, 2010. ,
DOI : 10.3324/haematol.2010.026708
Guideline for investigation and management of adults and children presenting with a thrombocytosis, British Journal of Haematology, vol.100, issue.Suppl 1, pp.352-75, 2010. ,
DOI : 10.1111/j.1365-2141.2010.08122.x
When to test for thrombophilia?]. Rev Prat, pp.1044-1050, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00683367
The V617F mutation of JAK2 is very uncommon in patients with thrombosis, Haematologica, vol.92, issue.2, pp.285-291, 2007. ,
DOI : 10.3324/haematol.10358
Etiological assessment of cerebral infarct in the young. Proposals from the working group of the French Neuro-vascular Society, Rev Neurol, vol.165, issue.4, pp.283-291, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00626970
Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival, European Journal of Haematology, vol.93, issue.5, pp.324-331, 2001. ,
DOI : 10.1056/NEJM200004273421706